Literature DB >> 30581091

Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.

Hongzheng Ren1, Xiaonan Hou2, Patrick W Eiken3, Jin Zhang4, Karlyn E Pierson5, Asha A Nair6, Jaime I Davila6, Helena Kovarikova7, Jin Sung Jang8, Sarah H Johnson9, Julian R Molina2, Randolph S Marks2, Ping Yang6, Joanne E Yi10, Aaron S Mansfield2, Jin Jen11.   

Abstract

Entities:  

Keywords:  5′ Fusion partner; Gene fusion; SCID-Beige mice; Survival; Targeted therapy

Mesh：

Substances：

Year:  2018        PMID： 30581091     DOI： 10.1016/j.cllc.2018.11.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  4 in total

Review 1.  A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.

Authors:  Chiho Miyagawa; Hisamitsu Takaya; Kazuko Sakai; Kazuto Nishio; Maho Konishi; Sachiko Minamiguchi; Toshihide Shimada; Noriomi Matsumura
Journal:  Oncologist       Date:  2021-02-22

Review 2.  Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.

Authors:  Mengnan Li; Zhou An; Qiusu Tang; Yutong Ma; Junrong Yan; Songan Chen; Yina Wang
Journal:  J Cell Mol Med       Date:  2021-09-19       Impact factor: 5.310

3.  Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.

Authors:  Kunyan Sun; Ligong Nie; Lin Nong; Yuan Cheng
Journal:  Thorac Cancer       Date:  2021-05-07       Impact factor: 3.500

4.  High STRN Expression Promotes HCC Invasion and Migration but Not Cell Proliferation or Apoptosis through Facilitating Epithelial-Mesenchymal Transition.

Authors:  Qian-Yu Du; Jing-Hao Yao; Yong-Chun Zhou; Ling-Jie Xu; Fu-You Zhao; Yan Yang
Journal:  Biomed Res Int       Date:  2020-03-23       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.